SALT LAKE CITY, May 17 /PRNewswire/ -- Amedica Corporation announced today it has elected Mr. Bradford S. Goodwin to its Board of Directors as of May 6, 2007.
Mr. Goodwin is currently a director of PDL BioPharma and Rigel, Inc. Prior to that he was the Chairman of the Board of CoTherix, Inc. and from 2001 to 2006 he was Chief Executive Officer and Director of Novacea, Inc. He has also held various senior executive positions with Genentech, Inc., including Vice President of Finance, with responsibility for treasury, purchasing, risk management, real estate, controllership, tax and long-range planning.
Mr. Goodwin was also an auditor at Pricewaterhouse Coopers where he served on expert advisory committees of the American Institute of Certified Public Accountants, the Financial Accounting Standards Board and International Accounting Standards Board.
"The Board of Directors and Management of Amedica are extremely pleased to extend a warm and enthusiastic welcome to Mr. Brad Goodwin as a new member of the Board of Directors of Amedica," said Ashok Khandkar, Chief Executive Officer of Amedica. "Brad's expertise in the financial arena along with his related experience in the health care sector provides him the insight to make a major contribution as Amedica advances its product candidates toward commercial introduction."
Amedica Corporation is an emerging orthopedic implant company focused on using its ceramics technologies to develop and commercialize a broad range of innovative spine and joint implants for the growing orthopedic device market. Its product candidates include spinal and reconstructive hip and knee implants that may represent a new standard of care in total joint implants based on superior durability, performance and safety.
Amedica CorporationCONTACT: Ashok C. Khandkar, Chief Executive Officer of AmedicaCorporation, +1-801-583-5100, ak@amedicacorp.com
Web site: http://www.amedicacorp.com/
